NASDAQ · Key Statistics

Evogene Ltd. (EVGN) P/E Ratio, ROE & Key Statistics

$0.34 NASDAQ: EVGN Market Cap $2.93M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Evogene Ltd. (EVGN), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-0.37
P/B ratioShare price divided by book value per share.-1.28
P/S ratioMarket value divided by annual revenue.2.27
PEG ratioP/E divided by the earnings growth rate.0.00
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.0.35
EV / RevenueEnterprise value against annual revenue.-3.24
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-232.56%
Free cash flow yieldFree cash flow as a percentage of market value.-400.90%

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.-14.16%
Operating marginRevenue left after operating costs.-350.00%
Net marginRevenue left after every cost, including tax and interest.-696.26%
Return on equityProfit as a percentage of shareholders’ equity.761.97%
Return on assetsProfit as a percentage of total assets.-67.68%
Return on capital employedOperating profit against the capital the business uses.-128.22%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.3.57
Quick ratioThe same, excluding inventory.3.54
Cash ratioCash alone against current liabilities.4.33
Debt to equityTotal borrowings against shareholders’ equity.-0.63
Debt to assetsTotal borrowings against total assets.0.10
Interest coverageHow many times operating profit covers the interest bill.-2.73

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$1.08
Market capitalisationShare price times shares outstanding.$2.93M
EmployeesReported headcount.117

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Evogene Ltd. (EVGN) statistics — frequently asked questions

What is Evogene Ltd.'s P/E ratio?

Evogene Ltd. (EVGN) trades on a price-to-earnings ratio of -0.37. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Evogene Ltd.'s return on equity?

Evogene Ltd. (EVGN) reports a return on equity of 761.97%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Evogene Ltd. carry?

Evogene Ltd. (EVGN) has a debt-to-equity ratio of -0.63, which compares total borrowings with shareholders' equity.

What is Evogene Ltd.'s profit margin?

Evogene Ltd. (EVGN) keeps -696.26% of revenue as net profit after every cost, including tax and interest.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.